Pseudopyloric Metaplasia Is Not Associated With the Development of Gastric Cancer.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
19
03
2021
accepted:
24
06
2021
pubmed:
28
7
2021
medline:
14
9
2021
entrez:
27
7
2021
Statut:
ppublish
Résumé
Corpus atrophic gastritis (CAG) is associated with intestinal metaplasia (IM) and pseudopyloric metaplasia (PPM). Prospective data on corpus mucosa PPM and its link to the development of gastric cancer (GC) are lacking. This study aimed to investigate the relationship between the presence of corpus mucosa PPM at baseline and the development of GC at follow-up in patients with CAG. A longitudinal cohort study was conducted on patients with consecutive CAG adhering to endoscopic-histological surveillance. Patients were stratified for the presence/absence of corpus PPM without concomitant corpus IM at baseline, and the occurrence of gastric neoplastic lesions at the longest available follow-up was assessed. A total of 292 patients with CAG with a follow-up of 4.2 (3-17) years were included. At baseline, corpus PPM without corpus IM was diagnosed in 62 patients (21.2%). At the follow-up, GC was detected in 5 patients (1.7%) and gastric dysplasia (GD) in 4 patients (1.4%). In all these 9 patients with GC/GD at the follow-up, corpus IM was present at baseline and follow-up. Age <50 years (odds ratio [OR] 2.5), absence of pernicious anemia (OR 4.3), and absence of severe corpus atrophy (OR 2.3) were associated with corpus PPM without corpus IM. At the 4.2-year follow-up, in patients with CAG characterized at baseline with corpus PPM without corpus IM, GC or GD was not observed because these lesions were consistently associated with corpus IM. Corpus PPM without corpus IM was associated with younger age, absence of pernicious anemia, and severe corpus atrophy, suggesting a lower stage of disease progression. Corpus PPM alone seems not to be associated with GC, whose development seems to require the presence of corpus IM as a necessary step.
Identifiants
pubmed: 34313623
doi: 10.14309/ajg.0000000000001390
pii: 00000434-202109000-00016
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1867Informations de copyright
Copyright © 2021 by The American College of Gastroenterology.
Références
Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: Interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002;16(7):1249–59.
Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis—Pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10(9):529–41.
Varbanova M, Frauenschläger K, Malfertheiner P. Chronic gastritis—An update. Best Pract Res Clin Gastroenterol 2014;28(6):1031–42.
D'Elios MM, Bergman MP, Azzurri A, et al. H(+),K(+)-atpase (proton pump) is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology 2001;120(2):377–86.
Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primers 2020;6(1):56.
Lahner E, Conti L, Annibale B, et al. Current perspectives in atrophic gastritis. Curr Gastroenterol Rep 2020;22(8):38.
Lahner E, Zagari RM, Zullo A, et al. Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig Liver Dis 2019;51(12):1621–32.
Correa P. Human gastric carcinogenesis: A multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52(24):6735–40.
Faber K. Gastritis and Its Consequences. Oxford University Press: New York and London, 1935.
Xia HH, Kalantar JS, Talley NJ, et al. Antral-type mucosa in the gastric incisura, body, and fundus (antralization): A link between Helicobacter pylori infection and intestinal metaplasia? Am J Gastroenterol 2000;95(1):114–21.
Kimura K, Takemoto T. An endoscopic recognition of the atrophic bor- der and its significance in chronic gastritis. Endoscopy 1969;1:87–97.
Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma. Lab Invest 1999;79(6):639–46.
Giroux V, Rustgi AK. Metaplasia: Tissue injury adaptation and a precursor to the dysplasia-cancer sequence. Nat Rev Cancer 2017;17(10):594–604.
Kuo HY, Chang WL, Yeh YC, et al. Spasmolytic polypeptide-expressing metaplasia associated with higher expressions of miR-21, 155, and 223 can be regressed by Helicobacter pylori eradication in the gastric cancer familial relatives. Helicobacter 2019;24(3):e12578.
Petersen CP, Mills JC, Goldenring JR. Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol 2016;3(1):11–26.
Burclaff J, Osaki LH, Liu D, et al. Targeted apoptosis of parietal cells is insufficient to induce metaplasia in stomach. Gastroenterology 2017;152(4):762–6.e7.
Amieva M, Peek RM Jr. Pathobiology of Helicobacter pylori-induced gastric cancer. Gastroenterology 2016;150(1):64–78.
Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: Reparative lineages in the gastrointestinal mucosa. J Pathol 2018;245(2):132–7.
Weis VG, Goldenring JR. Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009;12(4):189–97.
El-Zimaity HM, Ota H, Graham DY, et al. Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer 2002;94(5):1428–36.
von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014;12(12):1495–9.
Lahner E, Esposito G, Pilozzi E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol 2015;50(7):856–65.
Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): Guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44(1):74–94.
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of aGstrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019;51(4):365–88.
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20(10):1161–81.
Annibale B, Marignani M, Azzoni C, et al. Atrophic body gastritis: Distinct features associated with Helicobacter pylori infection. Helicobacter 1997;2(2):57–64.
Lahner E, Norman GL, Severi C, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009;104(8):2071–9.
Lahner E, Bordi C, Di Giulio E, et al. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment. Aliment Pharmacol Ther 2002;16(3):507–14.
Montgomery E, Voltaggio L. Biopsy Interpretation of the Gastro-Intestinal Tract Mucosa, 3rd edn. Wolters Kluver: Philadelphia, PA, 2018.
Leja M, Funka K, Janciauskas D, et al. Interobserver variation in assessment of gastric premalignant lesions: Higher agreement for intestinal metaplasia than for atrophy. Eur J Gastroenterol Hepatol 2013;25(6):694–9.
Genta RM. Recognizing atrophy: Another step toward a classification of gastritis. Am J Surg Pathol 1996;20(Suppl 1):S23–30.
Cotruta B, Gheorghe C, Iacob R, et al. The orientation of gastric biopsy samples improves the inter-observer agreement of the OLGA staging system. J Gastrointestin Liver Dis 2017;26(4):351–6.
Goldenring JR, Nam KT, Mills JC. The origin of pre-neoplastic metaplasia in the stomach: Chief cells emerge from the Mist. Exp Cell Res 2011;317(19):2759–64.
Goldenring JR, Nam KT, Wang TC, et al. Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: Time for reevaluation of metaplasias and the origins of gastric cancer. Gastroenterology 2010;138(7):2207–10.e1.
Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019;68(9):1545–75.
Nomura S, Yamaguchi H, Ogawa M, et al. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol 2005;288(2):G362–75.
Nomura S, Baxter T, Yamaguchi H, et al. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice. Gastroenterology 2004;127(2):582–94.
Nozaki K, Ogawa M, Williams JA, et al. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology 2008;134(2):511–22.
Waddingham W, Graham D, Banks M, et al. The evolving role of endoscopy in the diagnosis of premalignant gastric lesions. F1000Res 2018;7:F1000 Faculty Rev-715.
Lavery DL, Martinez P, Gay LJ, et al. Evolution of oesophageal adenocarcinoma from metaplastic columnar epithelium without goblet cells in Barrett's oesophagus. Gut 2016;65(6):907–13.
Biswas S, Quante M, Leedham S, et al. The metaplastic mosaic of Barrett's oesophagus. Virchows Arch 2018;472(1):43–54.
Hershko C, Ronson A, Souroujon M, et al. Variable hematologic presentation of autoimmune gastritis: Age-related progression from iron-deficiency to cobalamin depletion. Blood 2006;107(4):1673–9.
Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: A prospective screening study. Am J Gastroenterol 1999;94(3):766–72.
de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands. Gastroenterology 2008;134(4):945–52.
Xia HH, Lam SK, Wong WM, et al. Antralization at the edge of proximal gastric ulcers: Does Helicobacter pylori infection play a role? World J Gastroenterol 2003;9(6):1265–9.
Wada Y, Kushima R, Kodama M, et al. Histological changes associated with pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication. Virchows Arch 2020;477(4):489–96.
Rugge M, Sacchi D, Genta RM, et al. Histological assessment of gastric pseudopyloric metaplasia: Intra- and inter-observer consistency. Dig Liver Dis 2021;53(1):61–5.
Vannella L, Lahner E, Osborn J, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010;31:1042–50.
Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol 2004;57:177–82.
Nieuwenburg SAV, Mommersteeg MC, Eikenboom EL, et al. Factors associated with the progression of gastric intestinal metaplasia: A multicenter, prospective cohort study. Endosc Int Open 2021;9:E297–305.